Auranofin Is Highly Efficacious against Toxoplasma gondii In Vitro and in an In Vivo Experimental Model of Acute Toxoplasmosis

PLoS Neglected Tropical Diseases

Volumn 8, Issue 7, 2014, Pages

  Andrade, Rosa M ^a   Chaparro, Juan D ^b   Capparelli, Edmund ^b   Reed, Sharon L ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; ANTIPROTOZOAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIVISION; CELL INVASION; CELL VIABILITY; CHICKEN; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; EMBRYO; FIBROBLAST; FLUORESCENCE MICROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; NONHUMAN; PARASITE LOAD; REAL TIME POLYMERASE CHAIN REACTION; TACHYZOITE; TOXOPLASMA GONDII; TOXOPLASMOSIS; ANIMAL; CELL CULTURE; CELL SURVIVAL; CHICK EMBRYO; CYTOCHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG REPOSITIONING; DRUG SENSITIVITY; GROWTH, DEVELOPMENT AND AGING; IC50; PARASITOLOGY; PHYSIOLOGY; TOXOPLASMA; TREATMENT OUTCOME;

ANIMALS; ANTIPROTOZOAL AGENTS; AURANOFIN; CELL SURVIVAL; CELLS, CULTURED; CHICK EMBRYO; DISEASE MODELS, ANIMAL; DRUG REPOSITIONING; FIBROBLASTS; HISTOCYTOCHEMISTRY; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; PARASITE LOAD; PARASITIC SENSITIVITY TESTS; REAL-TIME POLYMERASE CHAIN REACTION; TOXOPLASMA; TOXOPLASMOSIS; TREATMENT OUTCOME;

EID: 84905510190     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002973     Document Type: Article

References (16)

1. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, et al. (2011) Foodborne illness acquired in the United States-major pathogens. Emerg Infect Dis 17: 7-15.
2. CDC (2013) Parasites- Toxoplasmosis (Toxoplasma infection). Available: http://www.cdc.gov/parasites/toxoplasmosis/. Accessed 3 July 2014.
3. Peters PJ, Thigpen MC, Parise ME, Newman RD, (2007) Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf 30: 481-501.
4. Rothova A, Bosch-Driessen LE, van Loon NH, Treffers WF, (1998) Azithromycin for ocular toxoplasmosis. Br J Ophthalmol 82: 1306-1308.
5. Sannella AR, Casini A, Gabbiani C, Messori L, Bilia AR, et al. (2008) New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications. FEBS Lett 582: 844-847.
6. Ilari A, Baiocco P, Messori L, Fiorillo A, Boffi A, et al. (2012) A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition. Amino Acids 42: 803-811.
7. Angelucci F, Sayed AA, Williams DL, Boumis G, Brunori M, et al. (2009) Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J Biol Chem 284: 28977-28985.
8. Debnath A, Parsonage D, Andrade RM, He C, Cobo ER, et al. (2012) A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med 18: 956-960.
9. Hirt RP, Muller S, Embley TM, Coombs GH, (2002) The diversity and evolution of thioredoxin reductase: new perspectives. Trends Parasitol 18: 302-308.
10. Gubbels MJ, Li C, Striepen B, (2003) High-throughput growth assay for Toxoplasma gondii using yellow fluorescent protein. Antimicrob Agents Chemother 47: 309-316.
11. Que X, Wunderlich A, Joiner KA, Reed SL, (2004) Toxopain-1 is critical for infection in a novel chicken embryo model of congenital toxoplasmosis. Infect Immun 72: 2915-2921.
12. Meneceur P, Bouldouyre MA, Aubert D, Villena I, Menotti J, et al. (2008) In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone. Antimicrob Agents Chemother 52: 1269-1277.
13. Gajria B, Bahl A, Brestelli J, Dommer J, Fischer S, et al. (2008) ToxoDB: an integrated Toxoplasma gondii database resource. Nucleic Acids Res 36: D553-556.
14. Glennas A, (1985) Auranofin treatment of rats: adaptation to intestinal adverse effects and observations on the cytosolic distribution of gold in the intestines, liver and kidneys. Acta Pharmacol Toxicol (Copenh) 56: 404-409.
15. Gottlieb NL (1986) Pharmacology of auranofin: overview and update. Scand J Rheumatol Suppl 63: 19-28.
16. Walz DT, DiMartino MJ, Griswold DE, Intoccia AP, Flanagan TL, (1983) Biologic actions and pharmacokinetic studies of auranofin. Am J Med 75: 90-108.